The United Kingdom and Singapore have launched negotiations for a new Mutual Recognition Agreement (MRA) covering pharmaceutical Good Manufacturing Practice (GMP). The negotiations began on 22 September 2026 and are intended to make medicines trade between the two countries more efficient by reducing duplicate inspection and testing requirements.
The proposed agreement builds on the existing UK-Singapore Free Trade Agreement and Digital Economy Agreement, while strengthening regulatory cooperation between the two countries.
What is the UK-Singapore pharmaceutical MRA?
A Mutual Recognition Agreement can allow regulators to recognise specified inspection or assessment results carried out by their counterparts.
Under the proposed UK-Singapore agreement, regulators would be able to mutually rely on laboratory inspection results for relevant pharmaceutical activities. This could reduce duplicated regulatory processes while maintaining the respective countries’ regulatory requirements.
Focus on Good Manufacturing Practice
The negotiations specifically concern pharmaceutical GMP, which relates to manufacturing standards and regulatory oversight for medicines.
The proposed MRA is intended to reduce administrative barriers associated with inspections and regulatory processes for eligible pharmaceutical trade between the UK and Singapore.
Why does the agreement matter for pharmaceutical trade?
Pharmaceuticals are an important part of the growing UK-Singapore trade relationship.
According to the UK Government:
- UK-Singapore goods trade was worth £12 billion in 2025.
- Total goods trade increased by 24% compared with 2024.
- UK-Singapore medicines trade was worth more than £300 million in 2025.
- The proposed MRA is expected to reduce costs and administrative barriers for medicines trade.
Potential impact on businesses
For pharmaceutical companies operating across the two markets, reducing duplicated inspections could help streamline certain regulatory processes.
The UK Government stated that the agreement would bring particular benefits to businesses in the South East of England, East of England and Wales, while supporting the wider life sciences sector.
UK and Singapore strengthen regulatory cooperation
The UK Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore’s Health Sciences Authority (HSA) are both members of the Access Consortium, which promotes regulatory cooperation.
The proposed MRA would build on this existing relationship and provide another framework for cooperation between the two pharmaceutical regulators.
Building on existing trade agreements
The pharmaceutical negotiations form part of the UK’s wider trade strategy and follow existing economic agreements between the UK and Singapore.
The proposed MRA would complement the countries’ existing Free Trade Agreement and Digital Economy Agreement, extending cooperation into pharmaceutical manufacturing standards and regulatory processes.
Note
The UK and Singapore have started negotiations; the announcement does not mean that a final Mutual Recognition Agreement is already in force.
Businesses involved in UK-Singapore pharmaceutical trade should therefore distinguish between the existing regulatory requirements and any future changes that may result from the negotiations.
Conclusion
The UK and Singapore have begun negotiations for a pharmaceutical GMP Mutual Recognition Agreement aimed at reducing duplicated regulatory processes and making medicines trade more efficient.
With UK-Singapore goods trade reaching £12 billion in 2025 and medicines trade exceeding £300 million, the proposed agreement could become an important part of the countries’ broader cooperation in life sciences and trade.
